{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:31:23Z","timestamp":1787020283509,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hebei Provincial Administration of Traditional Chinese Medicine","award":["Serial Number\uff1a2026343"],"award-info":[{"award-number":["Serial Number\uff1a2026343"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16156-2","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:16:38Z","timestamp":1778296598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of chemoimmunotherapy and inflammatory indices in stage III unresectable lung squamous cell carcinoma"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7030-9503","authenticated-orcid":false,"given":"Zhongfei","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5112-9012","authenticated-orcid":false,"given":"Chunwang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1849-1436","authenticated-orcid":false,"given":"Kun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"3","key":"16156_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics. 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"16156_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(4):249\u201374. https:\/\/doi.org\/10.6004\/jnccn.2204.0023.","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"16156_CR3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(12):1301\u201311. https:\/\/doi.org\/10.1200\/JCO.21.01308.","journal-title":"J Clin Oncol"},{"issue":"9","key":"16156_CR4","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1001\/jamaoncol.2024.1897","volume":"10","author":"HJ Ross","year":"2024","unstructured":"Ross HJ, Kozono D, Wang XF, et al. Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial. JAMA Oncol. 2024;10(9):1212\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1897.","journal-title":"JAMA Oncol"},{"issue":"12","key":"16156_CR5","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","volume":"17","author":"MC Garassino","year":"2022","unstructured":"Garassino MC, Mazieres J, Reck M, et al. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2022;17(12):1415\u201327. https:\/\/doi.org\/10.1016\/j.jtho.2022.07.1148.","journal-title":"J Thorac Oncol"},{"issue":"29","key":"16156_CR6","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst RS, Majem M, Barlesi F, et al. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(29):3383\u201393. https:\/\/doi.org\/10.1200\/JCO.22.00227.","journal-title":"J Clin Oncol"},{"key":"16156_CR7","doi-asserted-by":"publisher","unstructured":"Hui Z, Zhai Y, Men Y, et al. 72P Camrelizumab plus apatinib after chemoradiotherapy in unresectable stage III non-small cell lung cancer: A multi-center, single-arm, phase II study. Immuno-Oncol Technol. 2023;20. https:\/\/doi.org\/10.1016\/j.iotech.2023.100544.","DOI":"10.1016\/j.iotech.2023.100544"},{"issue":"6","key":"16156_CR8","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1158\/1078-0432.CCR-23-2568","volume":"30","author":"S Nakamichi","year":"2024","unstructured":"Nakamichi S, Kubota K, Misumi T, et al. Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study). Clin Cancer Res. 2024;30(6):1104\u201310. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2568.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"16156_CR9","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/cncr.33083","volume":"126","author":"GA Durm","year":"2020","unstructured":"Durm GA, Jabbour SK, Althouse SK, et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14\u2013179. Cancer. 2020;126(19):4353\u201361. https:\/\/doi.org\/10.1002\/cncr.33083.","journal-title":"Cancer"},{"issue":"5","key":"16156_CR10","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.ijrobp.2021.12.150","volume":"112","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang T, Huang Y, et al. Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis. Int J Radiat Oncol Biol Phys. 2022;112(5):1154\u201364. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.12.150.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"16156_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijrobp.2021.12.176","volume":"113","author":"AK Bryant","year":"2022","unstructured":"Bryant AK, Sankar K, Strohbehn GW, et al. Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2022;113(1):60\u20135. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.12.176.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"20","key":"16156_CR12","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.[J].N Engl. J Med. 2017;377(20):1919. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"J Med"},{"issue":"2","key":"16156_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Chen M, Jiang O, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022;23(2):209\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(21)00630-6.","journal-title":"Lancet Oncol"},{"key":"16156_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejca.2022.04.033","volume":"171","author":"AK Bryant","year":"2022","unstructured":"Bryant AK, Sankar K, Zhao L, et al. De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. Eur J Cancer. 2022;171:55\u201363. https:\/\/doi.org\/10.1016\/j.ejca.2022.04.033.","journal-title":"Eur J Cancer"},{"key":"16156_CR15","doi-asserted-by":"publisher","unstructured":"Binnewies M, Roberts EW, Kersten K et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Med. 2018. https:\/\/doi.org\/10.1038\/s41591-018-0014-x.","DOI":"10.1038\/s41591-018-0014-x"},{"issue":"13","key":"16156_CR16","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.4161\/cc.8.13.8985","volume":"8","author":"TA Gonda","year":"2009","unstructured":"Gonda TA, Tu S, Wang TC. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle. 2009;8(13):2005\u201313. https:\/\/doi.org\/10.4161\/cc.8.13.8985.","journal-title":"Cell Cycle"},{"key":"16156_CR17","doi-asserted-by":"publisher","first-page":"1164535","DOI":"10.3389\/fonc.2023.1164535","volume":"13","author":"M Proietto","year":"2023","unstructured":"Proietto M, Crippa M, Damiani C, et al. Tumor heterogeneity: preclinical models, emerging technologies, and future applications. Front Oncol. 2023;13:1164535. https:\/\/doi.org\/10.3389\/fonc.2023.1164535.","journal-title":"Front Oncol"},{"key":"16156_CR18","doi-asserted-by":"publisher","first-page":"5879137","DOI":"10.1155\/2022\/5879137","volume":"2022","author":"T Chen","year":"2022","unstructured":"Chen T, Song C, Liang G, et al. Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib. Dis Markers. 2022;2022:5879137. https:\/\/doi.org\/10.1155\/2022\/5879137.","journal-title":"Dis Markers"},{"issue":"3","key":"16156_CR19","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.21037\/tlcr-21-43","volume":"10","author":"S Chen","year":"2021","unstructured":"Chen S, Li R, Zhang Z, Huang Z, et al. Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors. Transl Lung Cancer Res. 2021;10(3):1397\u2013407. https:\/\/doi.org\/10.21037\/tlcr-21-43.","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"16156_CR20","doi-asserted-by":"publisher","first-page":"e0268288","DOI":"10.1371\/journal.pone.0268288","volume":"17","author":"H Wang","year":"2022","unstructured":"Wang H, Li C, Yang R, et al. Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis. PLoS ONE. 2022;17(5):e0268288. https:\/\/doi.org\/10.1371\/journal.pone.0268288.","journal-title":"PLoS ONE"},{"issue":"1","key":"16156_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.21037\/jgo-23-808","volume":"15","author":"S Matsas","year":"2024","unstructured":"Matsas S, Aguiar PN Jr, Del Giglio A. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers to prognosticate survival in advanced gastric cancer patients in the era of immunotherapy: a systematic review and meta-analysis. J Gastrointest Oncol. 2024;15(1):33\u201351. https:\/\/doi.org\/10.21037\/jgo-23-808.","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"16156_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12885-021-07784-x","volume":"21","author":"K Zhao","year":"2021","unstructured":"Zhao K, Wang C, Shi F, et al. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy. BMC Cancer. 2021;21(1):66. https:\/\/doi.org\/10.1186\/s12885-021-07784-x.","journal-title":"BMC Cancer"},{"key":"16156_CR23","doi-asserted-by":"publisher","first-page":"1094378","DOI":"10.3389\/fimmu.2023.1094378","volume":"14","author":"L Zheng","year":"2023","unstructured":"Zheng L, Xiong A, Wang S, et al. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer. Front Immunol. 2023;14:1094378. https:\/\/doi.org\/10.3389\/fimmu.2023.1094378.","journal-title":"Front Immunol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16156-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16156-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16156-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:38:29Z","timestamp":1782945509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16156-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16156"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16156-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective study that has been approved by our hospital's ethics committee (Office of the Ethics Committee, The Fourth Hospital of Hebei Medical University). The protocol was approved by Office of the Ethics Committee, The Fourth Hospital of Hebei Medical University in accordance with the guidelines of the ethics committee listed in the ethics statement. Our study adhered to the Declaration of Helsinki to this effect in the \u2018Ethics approval and consent to participate\u2019 section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"800"}}